1217 related articles for article (PubMed ID: 33396184)
21. [Role of ACE2 in COVID-19].
Imai Y
Nihon Yakurigaku Zasshi; 2022; 157(2):115-118. PubMed ID: 35228442
[TBL] [Abstract][Full Text] [Related]
22. The renin-angiotensin system and specifically angiotensin-converting enzyme 2 as a potential therapeutic target in SARS-CoV-2 infections.
Ferrara F; Vitiello A
Naunyn Schmiedebergs Arch Pharmacol; 2021 Jul; 394(7):1589-1593. PubMed ID: 34151392
[TBL] [Abstract][Full Text] [Related]
23. Scientific Hypothesis for Treatment of COVID-19's Lung Lesions by Adjusting ACE/ACE2 Imbalance.
Ferrara F; Vitiello A
Cardiovasc Toxicol; 2021 Jun; 21(6):498-503. PubMed ID: 33835386
[TBL] [Abstract][Full Text] [Related]
24. A comprehensive guide to the pharmacologic regulation of angiotensin converting enzyme 2 (ACE2), the SARS-CoV-2 entry receptor.
Oz M; Lorke DE; Kabbani N
Pharmacol Ther; 2021 May; 221():107750. PubMed ID: 33275999
[TBL] [Abstract][Full Text] [Related]
25. Multifunctional angiotensin converting enzyme 2, the SARS-CoV-2 entry receptor, and critical appraisal of its role in acute lung injury.
Oz M; Lorke DE
Biomed Pharmacother; 2021 Apr; 136():111193. PubMed ID: 33461019
[TBL] [Abstract][Full Text] [Related]
26. Identification of SARS-CoV-2 Receptor Binding Inhibitors by In Vitro Screening of Drug Libraries.
David AB; Diamant E; Dor E; Barnea A; Natan N; Levin L; Chapman S; Mimran LC; Epstein E; Zichel R; Torgeman A
Molecules; 2021 May; 26(11):. PubMed ID: 34072087
[TBL] [Abstract][Full Text] [Related]
27. Disequilibrium between the classic renin-angiotensin system and its opposing arm in SARS-CoV-2-related lung injury.
Sarzani R; Giulietti F; Di Pentima C; Giordano P; Spannella F
Am J Physiol Lung Cell Mol Physiol; 2020 Aug; 319(2):L325-L336. PubMed ID: 32639866
[TBL] [Abstract][Full Text] [Related]
28. Searching therapeutic strategy of new coronavirus pneumonia from angiotensin-converting enzyme 2: the target of COVID-19 and SARS-CoV.
Li SR; Tang ZJ; Li ZH; Liu X
Eur J Clin Microbiol Infect Dis; 2020 Jun; 39(6):1021-1026. PubMed ID: 32285293
[TBL] [Abstract][Full Text] [Related]
29. Angiotensin-converting enzyme 2, coronavirus disease 2019, and abdominal aortic aneurysms.
Xu B; Li G; Guo J; Ikezoe T; Kasirajan K; Zhao S; Dalman RL
J Vasc Surg; 2021 Nov; 74(5):1740-1751. PubMed ID: 33600934
[TBL] [Abstract][Full Text] [Related]
30. ACE2: from protection of liver disease to propagation of COVID-19.
Warner FJ; Rajapaksha H; Shackel N; Herath CB
Clin Sci (Lond); 2020 Dec; 134(23):3137-3158. PubMed ID: 33284956
[TBL] [Abstract][Full Text] [Related]
31. An ACE2 Microbody Containing a Single Immunoglobulin Fc Domain Is a Potent Inhibitor of SARS-CoV-2.
Tada T; Fan C; Chen JS; Kaur R; Stapleford KA; Gristick H; Dcosta BM; Wilen CB; Nimigean CM; Landau NR
Cell Rep; 2020 Dec; 33(12):108528. PubMed ID: 33326798
[TBL] [Abstract][Full Text] [Related]
32. ACE2 (Angiotensin-Converting Enzyme 2) in Cardiopulmonary Diseases: Ramifications for the Control of SARS-CoV-2.
Sharma RK; Stevens BR; Obukhov AG; Grant MB; Oudit GY; Li Q; Richards EM; Pepine CJ; Raizada MK
Hypertension; 2020 Sep; 76(3):651-661. PubMed ID: 32783758
[TBL] [Abstract][Full Text] [Related]
33. Flavonols as potential antiviral drugs targeting SARS-CoV-2 proteases (3CL
Mouffouk C; Mouffouk S; Mouffouk S; Hambaba L; Haba H
Eur J Pharmacol; 2021 Jan; 891():173759. PubMed ID: 33249077
[TBL] [Abstract][Full Text] [Related]
34. Renin-angiotensin system at the interface of COVID-19 infection.
Gul R; Kim UH; Alfadda AA
Eur J Pharmacol; 2021 Jan; 890():173656. PubMed ID: 33086029
[TBL] [Abstract][Full Text] [Related]
35. A super-potent tetramerized ACE2 protein displays enhanced neutralization of SARS-CoV-2 virus infection.
Miller A; Leach A; Thomas J; McAndrew C; Bentley E; Mattiuzzo G; John L; Mirazimi A; Harris G; Gamage N; Carr S; Ali H; Van Montfort R; Rabbitts T
Sci Rep; 2021 May; 11(1):10617. PubMed ID: 34012108
[TBL] [Abstract][Full Text] [Related]
36. Distinctive Roles of Furin and TMPRSS2 in SARS-CoV-2 Infectivity.
Essalmani R; Jain J; Susan-Resiga D; Andréo U; Evagelidis A; Derbali RM; Huynh DN; Dallaire F; Laporte M; Delpal A; Sutto-Ortiz P; Coutard B; Mapa C; Wilcoxen K; Decroly E; Nq Pham T; Cohen ÉA; Seidah NG
J Virol; 2022 Apr; 96(8):e0012822. PubMed ID: 35343766
[TBL] [Abstract][Full Text] [Related]
37. An albumin-angiotensin converting enzyme 2-based SARS-CoV-2 decoy with FcRn-driven half-life extension.
Fuchs E; Rudnik-Jansen I; Dinesen A; Selnihhin D; Mandrup OA; Thiam K; Kjems J; Pedersen FS; Howard KA
Acta Biomater; 2022 Nov; 153():411-418. PubMed ID: 36162760
[TBL] [Abstract][Full Text] [Related]
38. Downregulation of Membrane-bound Angiotensin Converting Enzyme 2 (ACE2) Receptor has a Pivotal Role in COVID-19 Immunopathology.
Vieira C; Nery L; Martins L; Jabour L; Dias R; Simões E Silva AC
Curr Drug Targets; 2021; 22(3):254-281. PubMed ID: 33081670
[TBL] [Abstract][Full Text] [Related]
39. NSP6 inhibits the production of ACE2-containing exosomes to promote SARS-CoV-2 infectivity.
Lv X; Chen R; Liang T; Peng H; Fang Q; Xiao S; Liu S; Hu M; Yu F; Cao L; Zhang Y; Pan T; Xi Z; Ding Y; Feng L; Zeng T; Huang W; Zhang H; Ma X
mBio; 2024 Mar; 15(3):e0335823. PubMed ID: 38303107
[TBL] [Abstract][Full Text] [Related]
40. Human cell receptors: potential drug targets to combat COVID-19.
Raghav PK; Kalyanaraman K; Kumar D
Amino Acids; 2021 Jun; 53(6):813-842. PubMed ID: 33950300
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
